CK
AXN

Carnick & Kubik’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Carnick & Kubik’s Portfolio AXN Stock Details AXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-150
Closed -$222 – 384
2015
Q3 		$222 Buy
+150
New +$236 ﹤0.01% 408

Other funds holding AXN

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
MA
MUFG Americas New York $4.04B AUM 12.45% 1-Year Est. Return

Carnick & Kubik's AXN Position: Q4 2015 in Review

Carnick & Kubik sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q4 2015, closing a stake of 150 shares — an estimated $222 sold.

Carnick & Kubik first reported a position in AXN in Q3 2015 and held it in 1 quarter. The position peaked at $222 in Q3 2015. 14 funds tracked by Wall St. Rank hold AXN as of Q4 2015.

  • Carnick & Kubik reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q4 2015 after selling out during the quarter.
  • Carnick & Kubik sold 150 Aoxing Pharmaceutical Company Inc. shares in Q4 2015, an estimated $222.
  • Carnick & Kubik first reported a position in Aoxing Pharmaceutical Company Inc. in Q3 2015 and held it in 1 quarter.
  • Carnick & Kubik's Aoxing Pharmaceutical Company Inc. position peaked at $222 in Q3 2015.
  • 14 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q4 2015.

Based on Carnick & Kubik's 13F filing for Q4 2015, filed 11 Feb 2016.